Ligand director exercises options, sells 2,161 shares
Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Director John L. LaMattina of LIGAND PHARMACEUTICALS INC exercised stock options and sold the resulting shares. He exercised a non-qualified stock option for 2,161 shares of common stock at an exercise price of $114.15 per share, then sold 2,161 shares of common stock in an open-market transaction at $200.76 per share on the same day. Following these transactions, he directly holds 30,724 shares of Ligand common stock. The option position associated with these 2,161 shares is now fully exercised.
Insider Trade Summary
Exercise and Sale: 2,161 shares ($187K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
LAMATTINA JOHN L
Role
Director
Sold
2,161 shs ($434K)
Approx. gross sale proceeds
$434K
Approx. exercise cost
$247K
Approx. pre-tax spread
$187K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 2,161 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,161 | $114.15 | $247K |
| Sale | Common Stock | 2,161 | $200.76 | $434K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 30,724 shares (Direct)
Footnotes (1)
- F1. This Option was previously reported as a Grant of 2,474 shares, which vested in full on June 6, 2019, at an exercise price of $195.91 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
Key Figures
Options exercised: 2,161 shares
Exercise price: $114.15 per share
Shares sold: 2,161 shares
+2 more
5 metrics
Options exercised
2,161 shares
Non-qualified stock option exercised March 6, 2026
Exercise price
$114.15 per share
Strike price for 2,161-share option
Shares sold
2,161 shares
Open-market sale on March 6, 2026
Sale price
$200.76 per share
Price received for common stock sale
Shares owned after transaction
30,724 shares
Direct Ligand common stock holdings post-trade
Key Terms
Non-Qualified Stock Option, derivative security, open-market sale, exercise price, +1 more
5 terms
Non-Qualified Stock Option financial
"security_title: "Non-Qualified Stock Option (right to buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
exercise price financial
"at an exercise price of $195.91 per share, but was adjusted"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
separation financial
"adjusted pursuant to the OmniAb Inc. separation from the issuer"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Ligand (LGND) director John L. LaMattina report in this Form 4?
John L. LaMattina exercised stock options for 2,161 Ligand shares and sold 2,161 common shares in an open-market transaction. These trades reflect an exercise-and-sell sequence on the same day, updating his direct ownership position in Ligand stock.
What options did John L. LaMattina exercise in the latest Ligand (LGND) filing?
He exercised a non-qualified stock option covering 2,161 shares of Ligand common stock at an exercise price of $114.15 per share. The option, originally granted in 2019 and later adjusted after the OmniAb separation, is now fully exercised.
Was the Ligand (LGND) option grant to John L. LaMattina previously adjusted?
Yes. The option was originally reported as a grant of 2,474 shares vesting June 6, 2019 at a $195.91 exercise price, but it was later adjusted in connection with the separation of OmniAb Inc. from Ligand, as disclosed in the footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
